Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: the 302 study

Overview of attention for article published in Blood, December 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 13 news outlets
blogs: 2 blogs
policy: 2 policy sources

twitter: 13 X users
patent: 3 patents
wikipedia: 1 Wikipedia page

Citations

dimensions_citation: 245 Dimensions

Readers on

mendeley: 217 Mendeley

Summary News Blogs Policy documents X Patents Wikipedia Dimensions citations

So far, Altmetric has seen 14 X posts from 13 X users, with an upper bound of 74,862 followers.

RT @SCTNB: Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: the 302 study | Blood Journal https://…

08 Feb 2019

Reply Repost Favourite

Ravulizumab every 8 weeks is noninferior to eculizumab every 2 weeks across all efficacy end points in eculizumab-experienced PNH pts. Pts with PNH may be safely & effectively switched from labeled-dose eculizumab every 2 weeks to ravulizumab every 8 w

08 Feb 2019

Reply Repost Favourite

Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: the 302 study https://t.co/rPxXkSqkF4 https://t.co/qndfXZ12Vc

08 Feb 2019

Reply Repost Favourite

RT @SCTNB: Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: the 302 study | Blood Journal https://…

08 Feb 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 10 additional X posts.